ANTICANCER VACCINE ADJUVANT COMPRISING INACTIVATED BACILLUS SUBTILIS SPORE AS ACTIVE INGREDIENT

摘要

The present invention provides an anticancer vaccine adjuvant and anticancer pharmaceutical composition, both of which comprise inactivated Bacillus subtilis spores as an active ingredient, and induces and increases Th1 immune response. The present invention activates Th1 immune response by activating dendritic cells and particularly, achieves the effect of selectively killing cancer cells and cancer tissues by inducing the proliferation and activation of CD8^+T cells. The present invention is provided in a dry powder form which can be used in nasal and oral formulations capable of being administered through mucus membranes by being mixing mixed with water free of bacteria and heating materials prior to use, and also can be formulated in non-oral administration forms including hypodermic injection and intramuscular injection.;COPYRIGHT KIPO 2016